Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for weight loss and pain in overweight or obese adults with knee osteoarthritis
2015-005163-16Phase 4Completed
- Sponsor
- Parker Institute for Cancer Immunotherapy
- Start
- Mar 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in knee osteoarthritis (OA), obesity and Overweight comparing Diet intervention + Saxenda with Diet intervention + placebo (2 arms). Primary endpoints: Body weight change over 52 weeks and Pain reduction. Started Mar 2016; status: completed.
02
Drugs
03
Conditions
knee osteoarthritis (OA)obesityOverweight
Beyond the preview
Go deeper on 2015-005163-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005163-16.